TinaHashiRN said:

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

tyler_CSCS said:

The arithmetic is right and one caveat matters: a U-40 syringe changes the markings, not the volumes.

Bookmarking. The distinction being drawn above is the one nobody else makes. Printing the relevant bit and taking it with me.

TinaHashiRN said:

Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

That is the short version; the long version is somebody else's post.

BrianDallas92 said:

I reconstituted a 10mg vial with 2ml of bacteriostatic water and I want someone to check my unit arithmetic before I draw anything, because I keep…

Sharing my dosing arithmetic titration experience with compounded semaglutide — I have been tracking injection volumes meticulously:

Using 5mg/2mL concentration with 1cc insulin syringes:

• Month 1: 10 units (0.25mg) — mild appetite reduction
• Month 2: 20 units (0.5mg) — significant appetite suppression
• Month 3: 30 units (0.75mg) — custom intermediate dose
• Month 4: 40 units (1.0mg) — optimal for me, staying here

The beauty of compounded vials is you can do custom intermediate doses. My provider was great about tailoring to my response.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.